Hepion Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OQB
KI Holdings Ltd., through Donald Kivowitz, has acquired a 10.2% stake in Hepion Pharmaceuticals, Inc. via a private placement involving common stock and warrants.
OQB
SCHEDULE: Hepion Pharmaceuticals Exec Boosts Stake
A key executive at Hepion Pharmaceuticals has increased their beneficial ownership to 5.7% through recent stock and warrant purchases, signaling continued personal investment in the company.
OQB
Vincent LoPriore, Gravitas Capital LP, and Invictus Capital Advisors Pension Plan collectively increased their beneficial ownership of Hepion Pharmaceuticals, Inc. common stock to 26.2%.
OQB
Gary Stetz, interim CEO and director of Hepion Pharmaceuticals, has increased his beneficial ownership to 5.7% through recent share and warrant purchases.
OQB
Black Global 5 LLC, Red Global 3, LLC, and Darin Feinstein have jointly filed a Schedule 13D, reporting beneficial ownership of 10,000,000 shares of Hepion Pharmaceuticals, Inc. common stock, representing 11.1% of the class.
OQB
Executive Chairman Vincent LoPriore and affiliated entities report a combined 21.46% beneficial ownership stake in Hepion Pharmaceuticals, Inc.